Application of chelerythrine in treatment of triple-negative breast cancer
By cerebralis regulating the activity of myeloid immunosuppressive cells in the tumor microenvironment, the problem of difficult treatment of triple-negative breast cancer is solved, and more effective and less side effects are achieved, providing a new breast cancer treatment strategy .
Patent Information
- Application Number
- CN202411005482.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-25
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing breast cancer treatment methods have great side effects, are prone to drug resistance, and lack specificity. In particular, triple-negative breast cancer lacks clear therapeutic targets, making the treatment more difficult.
By using cerebralis to regulate the activity of myeloid immunosuppressive cells in the tumor microenvironment, inhibit the migration, invasion and tumor microenvironment of triple-negative breast cancer cells, and combine the anti-tumor activity of traditional Chinese medicine ingredients to provide breast cancer patients with more information. Effective treatment options with less side effects.
Targeting the tumor microenvironment, enhancing the body's immune response, providing natural and low-toxic anti-tumor treatment options, interfering with the proliferation, migration and invasion of tumor cells by affecting multiple signaling pathways, reducing tumor metastasis, and improving patients' treatment prognosis and quality of life.
Smart Images

Figure CN119033784A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to application of chelerythrine in treating triple-negative breast cancer. Background Art
[0002] Breast cancer, as the most common malignant tumor among women worldwide, continues to rise in incidence, posing a serious threat to women's health. Modern medicine mainly treats breast cancer through chemotherapy, endocrine therapy, targeted therapy, immunotherapy, and surgery, but these treatments have serious side effects, are prone to drug resistance, and lack specificity. Triple-negative breast cancer (TNBC) is particularly difficult to treat due to the lack of clear therapeutic targets.
[0003] The tumor microenvironment (TME) plays a crucial role in the occurrence, development and metastasis of breast cancer. Among them, myeloid immunosuppressive cells (MIC), including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), promote tumor growth and metastasis by inhibiting host immune responses. Therefore, regulating the tumor microenvironment, especially targeting MIC, provides a new strategy for the treatment of breast cancer. Modern studies have found that some traditional Chinese medicine ingredients, such as chelerythrine (CHE), have significant anti-tumor activity and can inhibit the proliferation and metastasis of tumor cells through multiple mechanisms. Summary of the invention
[0004] The technical problem to be solved by the present invention is to provide an application of chelerythrine in the treatment of triple-negative breast cancer, which provides breast cancer patients with a more effective treatment option with fewer side effects by regulating the tumor microenvironment, especially targeting MIC, and combining the anti-tumor activity of the traditional Chinese medicine ingredient CHE.
[0005] The technical problem to be solved by the present invention is achieved through the following technical solutions:
[0006] The invention discloses an application of chelerythrine in the preparation of a drug for treating triple-negative breast cancer. The chelerythrine treats the proliferation and metastasis of triple-negative breast cancer by regulating the activity of myeloid immunosuppressive cells (MIC) in the tumor microenvironment.
[0007] Preferably, the chelerythrine inhibits the proliferation and metastasis of tumor cells by inhibiting the migration, invasion and tumor microenvironment of triple-negative breast cancer cells.
[0008] Preferably, the chelerythrine inhibits triple-negative breast cancer cell proliferation, tumor angiogenesis and the number of MIC cells in the tumor microenvironment by reducing the expression levels of CD31, CD163 and Gr1+CD11b in tumor tissues.
[0009] A pharmaceutical composition for treating triple-negative breast cancer comprises chelerythrine as an effective ingredient. The pharmaceutical composition is used to regulate the activity of myeloid immunosuppressive cells (MIC) in the tumor microenvironment.
[0010] Preferably, the pharmaceutical composition comprises chelerythrine, and the chelerythrine is used as the sole active ingredient or in combination with other drugs, and the pharmaceutical composition is administered orally or by other routes of administration.
[0011] Preferably, the pharmaceutical composition treats triple-negative breast cancer by inhibiting tumor cell proliferation and invasion and affecting MIC in the tumor microenvironment.
[0012] A reagent for detecting MIC-related biomarkers in a tumor microenvironment is used in the preparation of a product for diagnosing triple-negative breast cancer.
[0013] Preferably, the MIC-related biomarker is at least one of CD163 and Gr1 / CD11b.
[0014] A kit for detecting triple-negative breast cancer biomarkers, wherein the biomarkers are MIC-related biomarkers in a tumor microenvironment, and the kit comprises antibodies or probes for detecting MIC-related biomarkers in a tumor microenvironment.
[0015] Preferably, the antibody or probe is used to specifically bind to at least one of CD163 and Gr1 / CD11b.
[0016] The above technical solution of the present invention has the following beneficial effects:
[0017] (1) Targeting the tumor microenvironment, especially the MIC, reduces tumor immunosuppression and thus enhances the body's immune response to tumors.
[0018] (2) Applying the traditional Chinese medicine ingredient CHE to provide a natural, low-toxic anti-tumor treatment option;
[0019] (2) CHE intervenes in the proliferation, migration and invasion of tumor cells through a multi-target mechanism by affecting multiple signaling pathways, including PI3K / Akt / mTOR, MAPK, etc.
[0020] (3) In vivo and in vitro experiments verified the regulatory effects of CHE on the migration and invasion ability of TNBC cells and the tumor microenvironment, providing a solid experimental basis for clinical application.
[0021] (4) Reduce tumor metastasis and improve patient prognosis and quality of life.
[0022] In summary, this application provides a new treatment strategy for triple-negative breast cancer, which is expected to improve the treatment effect and reduce side effects, and has important clinical application value and social significance. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] The accompanying drawings, which are incorporated in and constitute a part of the specification, illustrate embodiments of the invention and, together with the description, serve to explain the principles of the invention.
[0024] Figure 1 Cell migration experiment diagram (the left diagram shows the wound healing experiment results after 4T1 and MDA-MB-231 cells were treated with different concentrations of CHE for 24 hours, and the right diagram shows the statistical data and significant marks compared with the control group (*P<0.05)).
[0025] Figure 2 Figure 2 is a Transwell migration experiment diagram (the left figure shows the Transwell migration experiment results after 4T1 and MDA-MB-231 cells were treated with different concentrations of CHE for 24 hours, and the right figure shows the statistical data and significant marks compared with the control group (*P<0.05, **P<0.01)).
[0026] Figure 3 Transwell invasion experiment diagram (the left figure shows the invasion ability of 4T1 and MDA-MB-231 cells after treatment with different concentrations of CHE for 24 hours, and the right figure shows the statistical data and significant marks compared with the control group (*P<0.05, **P<0.01, ***P<0.001)).
[0027] Figure 4 Western Blot analysis (Western Blot analysis results of EMT-related proteins E-cadherin, Vimentin, SLUG, and SNAIL after different concentrations of CHE were applied to 4T1 and MDA-MB-231 cells for 24 hours, with β-actin as the loading control. Compared with 0 μM, *P<0.05, **P<0.01, ***P<0.001).
[0028] Figure 5 Western Blot analysis (Western Blot analysis results of invasion-related proteins MMP-2 and MMP-9 after different concentrations of CHE were applied to 4T1 and MDA-MB-231 cells for 24 hours, with β-actin as loading control. Compared with 0 μM, *P<0.05, **P<0.01).
[0029] Figure 6The live imaging images are as follows (the live imaging results of mice injected with 4T1-LUC cells into the tail vein and then orally administered with the specified dose of CHE for 3 consecutive weeks).
[0030] Figure 7 This is the effect of CHE on tumor lung nodules (gross images of mouse lung tissue and the number of lung nodules after the experiment, compared with the control group, **P<0.01).
[0031] Figure 8 This is a picture of mouse lung HE staining (CHE staining of 4T1-LUC mouse lung tissue tumor).
[0032] Fig. 9 The figures are immunohistochemical staining (A and B are the immunohistochemical staining results of fixed tumor sections from mice treated with 0.5% CMC-Na and CHE, respectively). DETAILED DESCRIPTION
[0033] Various exemplary embodiments of the present invention will now be described in detail. It should be noted that the relative arrangement of components and steps, numerical expressions and numerical values set forth in these embodiments do not limit the scope of the present invention unless otherwise specifically stated.
[0034] Chelerythrine is a benzophenanthridine alkaloid in chelerythrine plants, which is commonly found in plants such as the Poppy family and has pharmacological activities such as anti-tumor and antibacterial. Chelerythrine (CHE), also known as chelerythrine and chelerythrine quaternary ammonium base. The relative molecular mass is 348.37. The chemical structure is as follows:
[0035]
[0036] The tumor microenvironment (TME) is a complex pathological system that involves the interaction of a large number of cells (such as tumor cells, lymphatic endothelial cells, and myeloid immunosuppressive cells (MIC)), thereby providing a living environment for tumor cells and promoting tumor metastasis. In the TME, MICs (mainly including tumor-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs)) play an important role in suppressing T cell anti-tumor immune responses. MDSCs are a group of immature myeloid cells that are widely present in most cancer patients and mouse tumor models. MDSCs inhibit host immune responses, inhibit immunity by inhibiting functional T cells and NK cells and inducing Treg expansion, and promote tumor angiogenesis, thereby promoting tumor growth and progression. Gr1+Ly6 is an important marker of MDSCs, and there are a large number of reports on this study. Activated macrophages are divided into M1 and M2 phenotypes. In general, M1 macrophages promote inflammatory responses to invading pathogens and tumor cells, while M2 macrophages tend to exert an immunosuppressive phenotype, which is conducive to tumor progression. Even though TAMs exhibit two polarized phenotypes, they are considered to be M2-like phenotype-acquired macrophages and produce epidermal growth factor (EGF) and MMPs to accelerate tumor migration and angiogenesis in the TME. Therefore, the therapeutic strategy is to re-cultivate the M2 phenotype (pro-tumorigenic) into an anti-tumorigenic M1 phenotype (anti-tumorigenic) to prevent the promotion of TAMs in tumors. CD163 is an important marker of M2 macrophages, and there are a large number of reports on this research. As a complex pathological system, TME participates in the crosstalk between tumor cells and TIMPs to provide nutrients for tumor cells, improve survival rates, provide an environment for tumor cells, and accelerate tumor metastasis. There is increasing evidence that traditional Chinese medicine inhibits tumors and downregulates the inhibitory function of TIMPs, including TAMs, DCs, and MDSCs in tumors. So we chose murine 4T1 cells to inoculate BALB / C female mice in order to better study the effects of CHE on triple-negative breast cancer in vivo tumors and tumor microenvironment.
[0037] There are few reports on the effects of CHE on triple-negative breast cancer in vivo, and the effects on the tumor microenvironment are not clear. Therefore, this application uses 4T1 in situ inoculated mice to establish a triple-negative breast cancer animal model to explore the effects of CHE on 4T1 tumors and tumor microenvironment. The study of CHE's inhibitory effects on triple-negative breast cancer metastasis and microenvironment, as well as the potential molecular mechanism of CHE inhibiting triple-negative breast cancer metastasis and microenvironment, provides experimental basis for further development. The study of chelidonium provides a strong theoretical basis for the use of the traditional Chinese medicine chelidonium in the clinical treatment of triple-negative breast cancer metastasis.
[0038] Example 1 Cell scratch test
[0039] (1) Take 4T1 cells in the logarithmic growth phase, digest them, and adjust the cell concentration to 4×105 cell·mL -1 , MDA-MB-231 cells, after digestion, the cell concentration was adjusted to 1.5 × 10 5 cell·mL -1 , added to a 6-well plate in a volume of 2 ml, and carefully placed in a CO2 incubator for 24 h;
[0040] (2) On the second day, observe the cell status under a microscope to see whether the cells have formed a monolayer fusion. Draw a straight horizontal line on the back of the 6-well plate with a marker pen. Use a sterile 100 μL pipette tip to draw a horizontal line vertically in each well under the ruler. Use sterile PBS to wash the scratches to see if there are suspended cells. Wash three times.
[0041] (3) The prepared CHE was diluted with serum-free medium to the required drug concentration (3, 1.5, 0.75, 0 μM and 4, 2, 1, 0 μM) in a volume of 2 ml. A microscope was used to take pictures and record the scratch width.
[0042] (4) After 24 hours, make sure to take a photo of the width of the same position using a microscope. Repeat the experiment three times.
[0043] (5) Image J software was used to measure the scratch area of each group, and Graph Pad was used to plot the data.
[0044] (6) Cell healing rate = (cell spacing before healing - cell spacing after healing) / cell spacing before healing × 100%.
[0045] Example 2 Transwell migration assay
[0046] The Transwell assay uses the difference in FBS concentration between the upper and lower chambers to detect the vertical migration ability of cells.
[0047] (1) Two triple-negative breast cancer cells, 4T1 and MDA-MB-231, were taken in the logarithmic growth phase. After digestion, the cells were counted using FBS-free culture medium and the cell concentration was adjusted to 5×10 4 cell·mL -1 .
[0048] (2) 200 μL of serum-free cell suspension containing drugs was added to the upper chamber. The concentrations of CHE added to 4T1 cells were 3, 1.5, 0.75, and 0 μM, and the concentrations of CHE added to MDA-MB-231 cells were 4, 2, 1, and 0 μM. Culture medium containing 10% FBS was added to the wells of the lower chamber, with a volume of 600 μL.
[0049] (3) After 24 h of culture, the original culture medium in each well was removed using a sterile pipette, and 4% paraformaldehyde (600 μL) was added to each well and allowed to fix for 20 min. Next, 1% crystal violet stain was added to each well for staining for 10 min.
[0050] (4) After staining, the cells were carefully washed three times with PBS and allowed to air dry completely. Microscope observation, photographing and counting were performed. Six fields of view were randomly selected and the experiment was repeated three times.
[0051] Example 3 Transwell invasion assay
[0052] (1) Under sterile conditions, use the diluted Matrigel solution to evenly cover the upper chamber of the Transwell and place it in a carbon dioxide incubator for later use.
[0053] (2) Two triple-negative breast cancer cells, 4T1 and MDA-MB-231, were taken in the logarithmic growth phase. After digestion, the cells were counted using FBS-free culture medium and the cell concentration was adjusted to 5×10 4 cell·mL -1 .
[0054] (3) 200 μL of serum-free cell suspension containing drugs was added to the upper chamber. The concentrations of CHE added to 4T1 cells were 3, 1.5, 0.75, and 0 μM, and the concentrations of CHE added to MDA-MB-231 cells were 4, 2, 1, and 0 μM. Culture medium containing 10% FBS was added to the wells of the lower chamber at a volume of 600 μL.
[0055] (4) After 24 h of culture, the original culture medium in each well was removed using a sterile pipette, and 4% paraformaldehyde was added to each well in a volume of 600 μL and allowed to fix for 20 min. Next, 1% crystal violet stain was added to each well for staining for 10 min.
[0056] (5) After staining, the cells were carefully washed three times with PBS and allowed to air dry completely. Microscope observation, photographing and counting were performed. Six fields of view were randomly selected and the experiment was repeated three times.
[0057] Example 4 Western Blot Detection
[0058] Extraction of total cell protein:
[0059] (1) Two breast cancer cells, 4T1 and MDA-MB-231, were taken in the logarithmic growth phase. After digestion, the cell concentration was adjusted to 1.5×10 5 cell·mL -1 and 1×10 5 cell·mL -1, added to a 6-well plate in a volume of 2 ml, and carefully placed in a CO2 incubator for 24 h;
[0060] (2) After 24 h, CHE was added to 4T1 cells at a final concentration of 3, 1.5, 0.75, and 0 μM, and CHE was added to MDA-MB-231 cells at a final concentration of 4, 2, 1, and 0 μM, and culture was continued for 24 h;
[0061] (3) Prepare pre-cooled PBS and wash carefully twice with a pipette against the well wall. Add the prepared cell lysis buffer to each well of the 6-well plate. Then, use a cell scraper to gently scrape the bottom of the well plate. Use a pipette to gently blow and absorb the cells and place them into an EP tube. Blow and pump each tube 32 times.
[0062] (4) Centrifuge for 5 min (14000 g, 4°C) and carefully collect the supernatant of each group, which is the total cell protein.
[0063] BCA method to measure protein concentration:
[0064] (1) Prepare all materials and reagents, add the prepared protein standard into a 96-well plate, with volumes of 0, 1, 2, 4, 8, 12, 16, and 20 μL, and then add pre-cooled PBS to a final volume of 20 μL;
[0065] (2) The collected proteins from each group were diluted and added to a 96-well plate at a volume of 20 μL per well;
[0066] (3) Add 200 μL of BCA working solution to each well of the plate, react at a constant temperature for 30 min, place the plate after the reaction in an ELISA reader, detect the absorbance A value at 562 nm, draw a protein standard curve, and calculate the protein concentration of the sample to be tested;
[0067] (4) Based on the calculated protein concentration, dilute with PBS to keep the protein concentration of each group consistent. Use a pipette to add 6× loading buffer and blow evenly. Place in 100°C water for 5 minutes to denature the protein. Then divide and package for later use.
[0068] Example 5 SDS-PAGE
[0069] (1) Clean the glass plate: rinse the glass plate in water, then take out the glass plate with one hand and wipe it gently with a clean cloth. Wait until there is no residual glue on the glass plate, rinse it again, and put it in a clean wooden frame to dry.
[0070] (2) Align the two glass plates and place them in the card slots. After clamping, place them on the vertical card. After careful observation to ensure that there are no problems, take leak detection measures and prepare for glue filling.
[0071] (3) Prepare the separation gel according to the separation gel formula, and slowly inject the separation gel into the gap between the glass plates with a pipette. Stop when it is 1 cm below the lower edge of the comb (to prevent the gel holes from sticking and breaking), and gently add double distilled water to seal it. Let it stand at room temperature, wait for 5 minutes after the remaining separation gel solidifies, and then dry it with filter paper after water sealing. Prepare the separation gel according to the concentrated gel formula and quickly inject it. Quickly insert the comb to prevent bubbles. After the remaining separation gel solidifies, wait for 5 minutes for use.
[0072] (4) Slowly pull out the comb without damaging the gel holes, carefully add the protein sample and pre-stained protein marker into the comb space, and inject electrophoresis buffer into the electrophoresis tank. The inner tank and the outer tank are not connected, and the inner tank is higher than the outer tank. Perform electrophoresis for 100 minutes at a constant voltage of 100V.
[0073] (5) Transfer
[0074] After the electrophoresis is finished, cut the filter paper larger than the PVDF membrane, and the PVDF membrane larger than the separation gel. Take an appropriate amount of PVDF membrane and put it into methanol for activation for 1-2 minutes. Then put the filter paper on the electrotransfer, pour a small amount of transfer buffer to wet it, gently put the cut separation gel on the filter paper, take out the PVDF membrane in the transfer buffer, carefully put it on the filter paper (to avoid bubbles), pour a small amount of transfer buffer to wet it, and then take a piece of filter paper to carefully cover the PVDF membrane, and install the electrotransfer instrument. Transfer the membrane at 200mA for 90 minutes.
[0075] (6) Closed
[0076] Skim milk powder was dissolved in TBST to a concentration of 20%. After the transfer, the PVDF membrane was placed in the skim milk powder on a shaker and slowly rocked for 1.5 hours for blocking.
[0077] (7) Primary antibody incubation
[0078] Rabbit anti-β-Actin antibody, rabbit anti-E-cadherin, rabbit anti-Vimentin, rabbit anti-SLUG, rabbit anti-SNAIL, rabbit anti-MMP-2, and rabbit anti-MMP-9 were added. The primary antibody was diluted at a dilution ratio of 1:1000, and all antibodies were incubated overnight in a 4°C refrigerator. Rabbit anti-β-Actin antibody was selected as the internal reference.
[0079] (8) Secondary antibody incubation
[0080] The next day, the PVDF membrane was removed and washed with TBST for 3 times, each time for no less than 5 minutes. Then, the membrane was slowly incubated in the secondary antibody on a shaker for 1 hour. After the secondary antibody incubation, the membrane was washed with TBST for 3 times, each time for no less than 5 minutes.
[0081] (9) ECL development
[0082] Take 4 ml of ECL chemiluminescent liquid A and put it into a small box, then add 4 ml of ECL chemiluminescent liquid B to the small box, mix well and wait. After one minute, evenly drop it on the PVDF membrane, and after the reaction, press and expose it.
[0083] (10) Gel imaging analysis
[0084] The gel images were processed and the gray value of the target bands was quantitatively analyzed using Image J software.
[0085] Seventy BALB / C female mice were randomly divided into seven groups according to their body weight, with 10 mice in each group. The specific scheme is as follows:
[0086]
[0087] Rats in each group were given corresponding drugs by gavage once every 2 days for 3 consecutive weeks.
[0088] Immunohistochemistry
[0089] Tumor tissues were stained with Ki67, CD31, CD163 and Gr1+CD11b antibodies to observe tumor cell proliferation, migration and tumor microenvironment properties.
[0090] Histochemistry (SV two-step method):
[0091] After the last in vivo imaging test, the mice were processed and sampled. The tumor tissue was washed with physiological saline and fixed with 4% paraformaldehyde. The 4% paraformaldehyde in the container was replaced and soaked for 2 hours. The tissue was soaked and washed with PBS buffer for 15 minutes × 3 times. The tissue was placed in a mold and placed in a dehydrator. It was immersed in 62°C liquid paraffin for 2 hours × 2 times and embedded in an embedding machine. It was placed on a freezing table for 10 minutes and the wax block was removed. The slices were sliced using a microtome with a thickness of 3μm. The slices were dewaxed and endogenous peroxidase was inactivated, followed by antigen repair and blocking. The diluted primary antibody was added dropwise, incubated at 4°C overnight, and the secondary antibody was added dropwise for color development. Finally, the slides were counterstained and sealed, observed under a microscope, and photographed.
[0092] Immunofluorescence double labeling:
[0093] After the last in vivo imaging test, the mice were processed and sampled. The tumor tissue was washed with physiological saline and fixed with 4% paraformaldehyde. The 4% paraformaldehyde in the container was replaced and soaked for 2 hours. The tissue was soaked and washed with PBS buffer for 15 minutes × 3 times. The tissue was placed in a mold and placed in a dehydrator. It was immersed in 62℃ liquid paraffin for 2 hours × 2 times and embedded in an embedding machine. It was placed on a freezing table for 10 minutes and the wax block was removed. The slices were sliced using a microtome with a thickness of 3μm. The slices were dewaxed, antigen repaired, and blocked. The diluted primary antibody was added dropwise at 4℃ overnight. The secondary antibody was added dropwise for color development. Finally, the slides were counterstained and sealed, and the slides were observed under a microscope and photographed.
[0094] Forty BALB / C mice were randomly divided into five groups according to their body weight, with 10 mice in each group. The specific scheme is as follows:
[0095] Blank group: 0.4 ml of distilled water;
[0096] Chelerythrine high-dose group 0.5% CMC-Na 20 mg / kg;
[0097] Model group 0.5% CMC-Na 0.4ml;
[0098] Model + chelerythrine low-dose group 0.5% CMC-Na 10 mg / kg;
[0099] Model + chelerythrine high-dose group 0.5% CMC-Na 20 mg / kg;
[0100] Rats in each group were given corresponding drugs by gavage once every 2 days for 3 consecutive weeks.
[0101] In vivo imaging:
[0102] Mice should be anesthetized before the in vivo imaging experiment. The anesthesia conditions are a mixed gas containing oxygen and 2% isoflurane in a transparent sealed container. After the mice are anesthetized, the luciferase substrate is injected intraperitoneally for 5 minutes. The mice are placed in the in vivo imaging system for detection and photography. The detection is performed once a week.
[0103] HE staining:
[0104] After the last in vivo imaging test, the mice were processed and sampled. Lung tissue was washed with physiological saline and fixed with 4% paraformaldehyde. The 4% paraformaldehyde in the container was replaced and soaked for 2 hours. Soaked and washed with PBS buffer for 15 minutes × 3 times, the tissue was placed in a mold, put into a dehydrator, and immersed in 62℃ liquid paraffin for 2 hours × 2 times, and embedded with an embedding machine. Placed on a freezing table for 10 minutes, the wax block was removed. Slices were made using a microtome with a thickness of 3μm. Dewaxing, gradient water immersion, staining, sealing, microscopic observation and photography were performed in sequence.
[0105] in conclusion:
[0106] (1) Effects of CHE on the horizontal migration ability of two triple-negative breast cancer cells, 4T1 and MDA-MB-231:
[0107] Through the commonly used in vitro cell migration experiment scratch test, the proportion of scratch healing in the same position of each group at different times after drug administration was compared to observe the effect of CHE on the migration ability of two triple-negative breast cancer cells, 4T1 and MDA-MB-231.
[0108] The results show (such as Figure 1), after 24h treatment with different concentrations of CHE, the healing ratio of scratch area of 4T1 and MDA-MB-231 triple-negative breast cancer cells was significantly lower than that of the control group (P<0.05), indicating that CHE can reduce the horizontal migration ability of 4T1 and MDA-MB-231 cells.
[0109] (2) Effects of CHE on the vertical migration ability of 4T1 and MDA-MB-231 triple-negative breast cancer cells:
[0110] The effect of CHE on the vertical migration of two triple-negative breast cancer cells, 4T1 and MDA-MB-231, was investigated. A Transwell chamber experiment was used to observe the number of 4T1 and MDA-MB-231 triple-negative breast cancer cells that vertically crossed the membrane after CHE treatment for 24 hours.
[0111] The results show (such as Figure 2 ), after 24h treatment with different concentrations of CHE, the number of 4T1 and MDA-MB-231 triple-negative breast cancer cells that passed through the chamber membrane was significantly reduced compared with the control group (P<0.01), suggesting that CHE can reduce the vertical migration ability of 4T1 and MDA-MB-231 triple-negative breast cancer cells.
[0112] (3) Effects of CHE on the invasion and migration ability of two triple-negative breast cancer cells, 4T1 and MDA-MB-231:
[0113] To study the effect of CHE on the invasion ability of two triple-negative breast cancer cells, 4T1 and MDA-MB-231, the number of vertically invasive cells of two triple-negative breast cancer cells, 4T1 and MDA-MB-231, was observed in a matrix gel-coated chamber after CHE treatment for 24 h.
[0114] The results show (such as Figure 3 ), after 24h treatment with different concentrations of CHE, the number of cells of 4T1 and MDA-MB-231 triple-negative breast cancer cells that passed through the matrix gel chamber was significantly lower than that of the control group (P<0.001).
[0115] (4) Effects of CHE on the expression of EMT-related proteins in 4T1 and MDA-MB-231 triple-negative breast cancer cells:
[0116] Western Blot was used to detect the expression of EMT-related proteins in CHE triple-negative breast cancer cells, 4T1 and MDA-MB-231, after treatment with different concentrations of CHE for 24 hours.
[0117] The results show (such as Figure 4), after CHE treatment, the expression level of E-cadherin protein in 4T1 and MDA-MB-231 triple-negative breast cancer cells increased compared with the control group, while the expression levels of Vimentin, SLUG, and SNAIL proteins decreased in a dose-dependent manner.
[0118] (5) Effects of CHE on the expression of MMP-2 and MMP-9 in 4T1 and MDA-MB-231 triple-negative breast cancer cells:
[0119] Western Blot was used to detect the effects of different concentrations of CHE on two types of triple-negative breast cancer cells, 4T1 and MDA-MB-231, for 24 hours to explore the effects of CHE on the expression of MMP-2 and MMP-9 proteins in triple-negative breast cancer cells.
[0120] The results show (such as Figure 5 ), the expression levels of MMP-2 and MMP-9 proteins in 4T1 and MDA-MB-231 triple-negative breast cancer cells were decreased after CHE treatment in a dose-dependent manner.
[0121] (6) Effect of CHE on the size of lung metastatic tumors in tumor mice:
[0122] After 4T1 cells are transfected with a virus containing the luciferase gene, the cells can stably express luciferase. By injecting the reaction substrate luciferin potassium salt into the mouse's peritoneal cavity, the luciferase in the tumor cells in the animal body reacts with it to produce fluorescence. The fluorescence is captured and its intensity is measured using a live imaging device to reflect the size and distribution of tumor cells in the nude mouse, thereby measuring the metastatic ability of tumor cells.
[0123] The results show (such as Figure 6 ), the size and intensity of the fluorescence distribution of the lung tumors in each group of mice in the third week were significantly enhanced compared with those in the first week of modeling; in the third week, the size and intensity of the fluorescence distribution of the lung tumors in the high-dose CHE group were significantly reduced compared with those in the model group.
[0124] (7) Effects of CHE on the gross images of lung metastatic tumors and lung nodules:
[0125] After the last experiment, the mice were treated and lung tissues were obtained.
[0126] The general image shows (such as Figure 7 ): Compared with the control group, the number of tumor nodules in the lung tissue of mice in the drug-treated group was significantly reduced. The results of counting the number of lung tissue nodules showed that compared with the model group, the number of lung tissue nodules in the low-dose CHE group and the high-dose CHE group was significantly reduced, which was statistically significant (P<0.01).
[0127] (8) HE staining results:
[0128] HE staining was used to evaluate the effect of CHE on lung tumors in 4T1-LUC mice.
[0129] The results show (such as Figure 8 ), the lung tumors in the model group were larger and had normal morphology, while the lung tumors in the CHE group were smaller and had irregular morphology. This suggests that CHE destroys the pathological morphology of lung tumors in mice.
[0130] (9) Effects of CHE on the expression of Ki67, CD31, CD163 and Gr1+CD11b:
[0131] Paraffin-embedded tumor tissues were labeled with Ki67, CD31, CD163, and Gr1+CD11b antibodies for observing anti-tumor cell activity as well as angiogenesis and tumor microenvironment.
[0132] The results show (such as Fig. 9 ), CD31 and CD163 positive expression was brown or brownish yellow staining. Compared with the control group, the brown positive expression in the drug-treated group was reduced, and the high-dose CHE group had the best effect.
[0133] Gr1+CD11b positive expression showed yellow fluorescence. Compared with the control group, the positive expression of yellow fluorescence in the drug-treated group was reduced, and the high-dose CHE group had the best effect, indicating that CHE can inhibit tumor cell proliferation, metastasis and tumor microenvironment.
[0134] The experimental results showed that CHE reduced the expression level of CD31 in blood vessels in tumor tissues.
[0135] Gr1+Ly6 is an important marker of MDSCs, and CD163 is an important marker of M2 macrophages. There are a lot of reports on this. In addition, MDSCs can also differentiate into M2 macrophages, which promote T cell apoptosis and lead to immunosuppression. Immunohistochemistry results showed that CHE reduced the expression of CD163 and Gr1 / CD11b. It suggests that CHE can reduce the number and activity of MICs in the in vivo tumor microenvironment of the 4T1 breast cancer model, improve the tumor microenvironment, and inhibit the growth and metastasis of breast cancer.
[0136] Although the present invention has been disclosed as above by the embodiments, it is not intended to limit the present invention. Any person skilled in the art may make various choices and modifications without departing from the spirit and scope of the present invention. Therefore, the protection scope of the present invention is limited by the claims and their equivalents.
Claims
1. Application of chelerythrine in the preparation of drugs for treating triple-negative breast cancer, It is characterized in that The chelerythrine is used to treat triple-negative breast cancer by regulating the activity of myeloid immunosuppressive cells (MICs) in the tumor microenvironment.
2. The use according to claim 1, It is characterized in that The chelerythrine inhibits the proliferation and metastasis of tumor cells by inhibiting the migration, invasion and tumor microenvironment of triple-negative breast cancer cells.
3. The use according to claim 1, It is characterized in that The chelerythrine inhibits triple-negative breast cancer tumor angiogenesis and the number of MIC cells in the tumor microenvironment by reducing the expression levels of CD31, CD163 and Gr1+CD11b+ in tumor tissues.
4. A pharmaceutical composition for treating triple-negative breast cancer, It is characterized in that The pharmaceutical composition comprises chelerythrine as an effective ingredient and is used for regulating the activity of myeloid immunosuppressive cells (MIC) in the tumor microenvironment.
5. The pharmaceutical composition for treating triple-negative breast cancer according to claim 4, It is characterized in that The pharmaceutical composition contains chelerythrine, which is used as the only active ingredient or in combination with other drugs. The pharmaceutical composition is administered orally, by injection or other routes.
6. The pharmaceutical composition for treating triple-negative breast cancer according to claim 5, It is characterized in that The pharmaceutical composition treats triple-negative breast cancer by inhibiting tumor cell proliferation and invasion and affecting MIC in the tumor microenvironment.
7. Use of a reagent for detecting MIC-related biomarkers in the tumor microenvironment in the preparation of a product for diagnosing triple-negative breast cancer.
8. The use according to claim 7, It is characterized in that The MIC-related biomarker is at least one of CD163 and Gr1 / CD11b.
9. A kit for detecting triple-negative breast cancer biomarkers, It is characterized in that The biomarker is a MIC-related biomarker in a tumor microenvironment, and the kit comprises an antibody or a probe for detecting the MIC-related biomarker in a tumor microenvironment.
10. The biomarker detection kit according to claim 9, It is characterized in that The antibody or probe is used to specifically bind to at least one of CD163 and Gr1 / CD11b.
Citation Information
Patent Citations
Intraductal methods of treatment of breast disorders
US20210000920A1
Cited By
Bionic chelerythrine-loaded semiconductor polymer dot as well as preparation method and application thereof
CN120884698A
